Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.94 |
| ▸ | PPARG | P37231 | 7/20 | 0.94 |
| ▸ | PPARD | Q03181 | 7/20 | 0.94 |
| ▸ | PPARA | Q07869 | 7/20 | 0.94 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.94 |
| ▸ | TSHR | P16473 | 4/20 | 0.94 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.94 |
| ▸ | FABP4 | P15090 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | TLR2 | O60603 | 2/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.94 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.94 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.94 |
| ▸ | MEN1 | O00255 | 1/20 | 0.94 |
| ▸ | ESR1 | P03372 | 1/20 | 0.94 |
| ▸ | PDE4A | P27815 | 1/20 | 0.94 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptanoate SCHEMBL267660 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL1546700 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexacosanoic Acid SCHEMBL2411058 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL9296760 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL517385 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL455912 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL936 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL103018 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonadecanoic Acid SCHEMBL11324243 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL1362870 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022072099-A9 | IMMEDIATE RELEASE DOSAGE FORMS, METHODS OF MAKING AND USING | EIRGEN PHARMA, LTD (IE) | 2022-07-21 | — | — | WO | claimed |
| EP-3370703-A1 | GEMCABENE COMBINATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | Gemphire Therapeutics Inc. (US) | 2018-09-12 | — | — | EP | claimed |
| CN-108366957-A | Lucky Cabbeen for treating angiocardiopathy combines | 燿石治疗公司 | 2018-08-03 | — | — | CN | claimed |
| WO-2017079755-A1 | GEMCABENE COMBINATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | GEMPHIRE THERAPEUTICS INC. (US) | 2017-05-11 | — | — | WO | claimed |
| CN-104606070-A | Dry and comfortable powder capable of removing miliaria and relieving itching | AESTHETIC INTERNAT HOLDINGS CHAIN GROUP | 2015-05-13 | — | — | CN | claimed |
| EP-2566462-A1 | IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE | Jazz Pharmaceuticals Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| WO-2011139271-A1 | IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE | Jazz Pharmaceuticals, Inc. (US) | 2011-11-10 | — | — | WO | claimed |
| US-20110111027-A1 | IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE | Jazz Pharmaceuticals, Inc. (US) | 2011-05-12 | — | — | US | claimed |
| CN-120202205-A | Tri-ring PI3K alpha inhibitor, and preparation method and medical application thereof | 微境生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119998274-A | ULK inhibitors | 微境生物医药科技(上海)有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-116249702-B | 1,2, 4-Triazolone derivatives as DHODH inhibitors | 微境生物医药科技(上海)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-118598783-B | Mercaptophenol derivatives and use thereof | 暨南大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-118598760-B | Tetraphenyl ethylene derivative and application thereof | 暨南大学 | 2025-02-21 | — | — | CN | disclosed |
| CN-119451958-A | Compounds as MYT1 inhibitors | 微境生物医药科技(上海)有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-0068592-B1 | NOVEL CARBAMATE DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4443473-A | ANALGESICS, ANTIALLERGENS | THE PROCTER & GAMBLE COMPANY (US) | 1984-04-17 | — | — | US | disclosed |
| US-4401663-A | ANALGESICS, ANTI-IRRITANTS, DEPILATORIES | THE PROCTER & GAMBLE COMPANY (US) | 1983-08-30 | — | — | US | disclosed |
| EP-0068591-A2 | Novel sulfonamide derivatives | THE PROCTER & GAMBLE COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
| EP-0068592-A1 | Novel carbamate derivatives | THE PROCTER & GAMBLE COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
| US-3984559-A | Compositions comprising tetramic acid analogs of pulvinic acid and methods of combating arthritis | SMITHKLINE CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111027-A1 | IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE | GHSR, GHRHR, HBB | GPR84 512/4885PPARG 323/4885PPARD 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.